Publication | Closed Access

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

InflammationDouble-blind Phase 3Week 16Week 52MedicineClinical DermatologyDermatologyPsoriatic Arthritis